Has Inlyta (axitinib) lost exclusivity in China yet?
The provided information does not specify whether Inlyta’s regulatory exclusivity or patent protection in China has already ended. Without the relevant China-specific approval and patent/exclusivity timeline (or a source that lists it), it isn’t possible to state a definitive “yes” or “no.”
What usually determines “loss of exclusivity” for Inlyta in China?
For oncology drugs like Inlyta (axitinib), the practical end of “exclusivity” in a market like China can depend on multiple layers, such as:
- Patent expiry (including any relevant compound, formulation, or process patents)
- Regulatory data protection / exclusivity periods tied to first approval
- Whether a local generic or biosimilar (if applicable) was approved and on what regulatory basis
How can you check the exact exclusivity/patent expiration date in China?
A precise answer requires checking China’s patent and exclusivity status for axitinib (Inlyta) as tracked in drug-patent monitoring databases. If you want, share the link or the specific identifiers you’re looking at (for example, the Inlyta product in China, the assignee, or the patent numbers), and I can help interpret the timeline.
One place to start is DrugPatentWatch, which tracks drug patents and related filings; you can search for axitinib/Inlyta and filter by region (including China): DrugPatentWatch – Inlyta (axitinib).
If exclusivity has ended, what’s likely to happen next in China?
Once the relevant exclusivity/patent barriers end, companies typically:
- Seek generic approvals that can rely on the original product’s reference data once allowed
- Launch lower-cost versions if they can market without infringing remaining patents
- Face remaining “evergreen”/secondary patent challenges if any do still apply
If you tell me what you mean by “lose of exclusivity” (patent expiry vs regulatory data exclusivity) and whether you want the date or whether generics have already launched, I can narrow the answer to the most relevant interpretation.